Review
doi: 10.4103/0253-7613.161249.
Imiquimod - Its role in the treatment of cutaneous malignancies
Affiliations
- PMID: 26288465
- PMCID: PMC4527053
- DOI: 10.4103/0253-7613.161249
Item in Clipboard
Review
Imiquimod - Its role in the treatment of cutaneous malignancies
Indian J Pharmacol.
2015 Jul-Aug.
Abstract
Imiquimod is a synthetic imidazoquinolone amine, which has potent immune response modifier activity, when topically used. This characteristic property of imiquimod has led to its use in a number of applications in dermatology, particularly in cutaneous malignancies, where it has been found to be effective and safe. Currently, additional mechanisms for its activity in actinic keratosis, basal cell carcinoma, and invasive squamous cell carcinoma have been elucidated. Its usage for cutaneous metastasis in breast cancer has been a further addition to its therapeutic armamentarium recently.
Keywords: Cutaneous malignancies; imidazoquinolone; imiquimod.
Similar articles
-
The use of imiquimod in the treatment of periocular tumours.Orbit. 2010 Apr;29(2):83-7. doi: 10.3109/01676830903294909. Orbit. 2010. PMID: 20394545
-
Topical imiquimod therapy for basal and squamous cell carcinomas: a clinical experience.Cutis. 2007 Mar;79(3):241-8. Cutis. 2007. PMID: 17674590
-
Imiquimod 5 percent cream and the treatment of cutaneous malignancy.Dermatol Online J. 2004 Jul 15;10(1):4. Dermatol Online J. 2004. PMID: 15347486 Review.
-
Topical treatment of basal cell carcinoma with the immune response modifier imiquimod.Future Oncol. 2015 Nov;11(22):2985-90. doi: 10.2217/fon.15.192. Epub 2015 Oct 9. Future Oncol. 2015. PMID: 26450707 Review.
-
5% imiquimod cream for the treatment of large superficial basal cell carcinoma.Arch Dermatol. 2004 Oct;140(10):1286-7. doi: 10.1001/archderm.140.10.1286. Arch Dermatol. 2004. PMID: 15492202 Clinical Trial. No abstract available.
Cited by
-
The Toll-like receptor 7 agonist imiquimod increases ethanol self-administration and induces expression of Toll-like receptor related genes.Addict Biol. 2022 May;27(3):e13176. doi: 10.1111/adb.13176. Addict Biol. 2022. PMID: 35470561 Free PMC article.
-
Role of cytokine in malignant T-cell metabolism and subsequent alternation in T-cell tumor microenvironment.Front Oncol. 2023 Sep 7;13:1235711. doi: 10.3389/fonc.2023.1235711. eCollection 2023. Front Oncol. 2023. PMID: 37746258 Free PMC article. Review.
-
Systematic review of randomized controlled trials of topicals for actinic keratosis field therapy.Arch Dermatol Res. 2024 Mar 18;316(4):108. doi: 10.1007/s00403-024-02839-y. Arch Dermatol Res. 2024. PMID: 38498070 Review.
-
NOD2 activation enhances macrophage Fcγ receptor function and may increase the efficacy of antibody therapy.Front Immunol. 2024 Jun 11;15:1409333. doi: 10.3389/fimmu.2024.1409333. eCollection 2024. Front Immunol. 2024. PMID: 38919608 Free PMC article.
-
Precise delivery of doxorubicin and imiquimod through pH-responsive tumor microenvironment-active targeting micelles for chemo- and immunotherapy.Mater Today Bio. 2022 Nov 3;17:100482. doi: 10.1016/j.mtbio.2022.100482. eCollection 2022 Dec 15. Mater Today Bio. 2022. PMID: 36388459 Free PMC article.
References
-
- Sauder DN. Immunomodulatory and pharmacologic properties of imiquimod. J Am Acad Dermatol. 2000;43:S6–11. - PubMed
-
- Navi D, Huntley A. Imiquimod 5 percent cream and the treatment of cutaneous malignancy. Dermatol Online J. 2004;10:4. - PubMed
-
- Leverkus M. Imiquimod: Unexpected killer. J Invest Dermatol. 2004;122:XV–XVI. - PubMed
-
- Beutner KR, Geisse JK, Helman D, Fox TL, Ginkel A, Owens ML. Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. J Am Acad Dermatol. 1999;41:1002–7. - PubMed
-
- Jobanputra KS, Rajpal AV, Nagpur NG. Imiquimod. Indian J Dermatol Venereol Leprol. 2006;72:466–9. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
